Phase 3CompletedAge-related condition
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)
A Multicenter, Randomized, Double-blind, Double Dummy, Active-controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate the Efficacy and Safety of CWP-0403 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DM Insufficiently Controlled With Metformin Alone
- Sponsor
- JW Pharmaceutical (Industry)
- Enrollment
- 200 planned
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Anagliptin; Sitagliptin
- Ages
- adults, older adults
- Registry
- NCT01529541
Full record on ClinicalTrials.gov
From the registry
This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.
Primary outcomes
- The Change in HbA1c from baseline to week24.
History
Last registry update
Study completion
Primary completion
Registered
Started